Could a diabetes drug shield heart transplant patients from kidney failure?
NCT ID NCT05321706
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial tests whether dapagliflozin (Farxiga), a drug originally developed for diabetes, can protect kidney function in people who have received a heart transplant. Kidney failure is a common and serious complication after heart transplant. The study involves 430 participants who will take either dapagliflozin or a placebo daily for one year, with researchers measuring changes in kidney function and other health outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (Farxiga)
What this could lead to
If it works, this could offer a new way to protect kidney function in heart transplant patients, reducing the risk of kidney failure and improving long-term outcomes.
What could go wrong
This is a Phase 3 trial, but SGLT2 inhibitors have not been tested in heart transplant recipients before, so unexpected side effects or lack of benefit are possible. The trial lasts one year, so long-term effects are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Karolinska University Hospital
Stockholm, Sweden
-
Oslo University Hospital, Rikshospitalet
Oslo, Oslo, 0372, Norway
-
Skane University Hospital
Lund, 22185, Sweden
-
University Medical Center Groningen
Groningen, Netherlands
-
University Medical Center Utrecht
Utrecht, 3584, Netherlands